相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The Toll-like receptor 7/8 agonist resiquimod greatly increases the immunostimulatory capacity of human acute myeloid leukemia cells
Evelien L. J. M. Smits et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
IL-7 is superior to IL-2 for ex vivo expansion of tumour-specific CD4+ T cells
Stefano Caserta et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2010)
Immune responses to malignancies
Theresa L. Whiteside
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2010)
Mechanism of T Cell Tolerance Induced by Myeloid-Derived Suppressor Cells
Srinivas Nagaraj et al.
JOURNAL OF IMMUNOLOGY (2010)
Clinical Use of Anti-CD25 Antibody Daclizumab to Enhance Immune Responses to Tumor Antigen Vaccination by Targeting Regulatory T cells
Andrew J. Rech et al.
CANCER VACCINES (2009)
Monoclonal Antibodies Targeting Vascular Endothelial Growth Factor Current Status and Future Challenges in Cancer Therapy
Jerry Y. Hsu et al.
BIODRUGS (2009)
Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion
Roch Houot et al.
BLOOD (2009)
Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters
Lotte Engell-Noerregaard et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Triggering of Toll-like Receptor 4 Expressed on Human Head and Neck Squamous Cell Carcinoma Promotes Tumor Development and Protects the Tumor from Immune Attack
Miroslaw J. Szczepanski et al.
CANCER RESEARCH (2009)
Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy
E. Martinelli et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2009)
Effect of Granulocyte/Macrophage Colony-Stimulating Factor on Vaccination with an Allogeneic Whole-Cell Melanoma Vaccine
Mark B. Faries et al.
CLINICAL CANCER RESEARCH (2009)
Immunostimulation Versus Immunosuppression after Multiple Vaccinations: the Woes of Therapeutic Vaccine Development
Alexander M. M. Eggermont
CLINICAL CANCER RESEARCH (2009)
Synergistic Enhancement of CD8+ T Cell-Mediated Tumor Vaccine Efficacy by an Anti-Transforming Growth Factor-β Monoclonal Antibody
Masaki Terabe et al.
CLINICAL CANCER RESEARCH (2009)
Partial CD4 Depletion Reduces Regulatory T Cells Induced by Multiple Vaccinations and Restores Therapeutic Efficacy
Michael G. LaCelle et al.
CLINICAL CANCER RESEARCH (2009)
New Perspectives for Melanoma Immunotherapy: Role of IL-12
Claudia Cocco et al.
CURRENT MOLECULAR MEDICINE (2009)
Antigen choice in adoptive T-cell therapy of cancer
Rienk Offringa
CURRENT OPINION IN IMMUNOLOGY (2009)
Adenosine: An endogenous modulator of innate immune system with therapeutic potential
Vijay Kumar et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2009)
Countering tumor-induced immunosuppression during immunotherapy for pancreatic cancer
Michael A. Morse et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2009)
Ten years of rituximab in NHL
Matthew C. Winter et al.
EXPERT OPINION ON DRUG SAFETY (2009)
A Low Interleukin-2 Receptor Signaling Threshold Supports the Development and Homeostasis of T Regulatory Cells
Aixin Yu et al.
IMMUNITY (2009)
PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4(+)CD25(Hi) regulatory T cells
Wenshi Wang et al.
INTERNATIONAL IMMUNOLOGY (2009)
The tumor-promoting actions of TNF-α involve TNFR1 and IL-17 in ovarian cancer in mice and humans
Kellie A. Charles et al.
JOURNAL OF CLINICAL INVESTIGATION (2009)
Human Circulating CD4+CD25highFoxp3+ Regulatory T Cells Kill Autologous CD8+ but Not CD4+ Responder Cells by Fas-Mediated Apoptosis
Laura Strauss et al.
JOURNAL OF IMMUNOLOGY (2009)
Tumor-Derived Microvesicles Promote Regulatory T Cell Expansion and Induce Apoptosis in Tumor-Reactive Activated CD8+ T Lymphocytes
Eva U. Wieckowski et al.
JOURNAL OF IMMUNOLOGY (2009)
Engineered Interleukin-2 Antagonists for the Inhibition of Regulatory T Cells
David V. Liu et al.
JOURNAL OF IMMUNOTHERAPY (2009)
Molecular mechanisms of resistance to Rituximab and pharmacologic strategies for its circumvention
Claudia Stolz et al.
LEUKEMIA & LYMPHOMA (2009)
Immunotherapeutic strategies in kidney cancer - when TKIs are not enough
Swethajit Biswas et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2009)
Tumour-initiating cells: challenges and opportunities for anticancer drug discovery
Bin-Bing S. Zhou et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
The biology of interleukin-2 efficacy in the treatment of patients with renal cell carcinoma
Antonio Romo de Vivar Chavez et al.
MEDICAL ONCOLOGY (2009)
Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival
Dusan Bogunovic et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Gene and chromosomal alterations in sporadic breast cancer: correlation with histopathological features and implications for genesis and progression
Hitoshi Tsuda
BREAST CANCER (2009)
Myeloid-derived suppressor cells as regulators of the immune system
Dmitry I. Gabrilovich et al.
NATURE REVIEWS IMMUNOLOGY (2009)
A clinical study assessing the tolerability and biological effects of infliximab, a TNF-α inhibitor, in patients with advanced cancer
E. R. Brown et al.
ANNALS OF ONCOLOGY (2008)
Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines
Michael A. Morse et al.
BLOOD (2008)
TGF-β:: A master of all T cell trades
Ming O. Li et al.
CELL (2008)
Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients
James H. Finke et al.
CLINICAL CANCER RESEARCH (2008)
The role of vaccine therapy in the treatment of melanoma
Marko Lens
EXPERT OPINION ON BIOLOGICAL THERAPY (2008)
Signaling defects in anti-tumor T cells
Alan B. Frey et al.
IMMUNOLOGICAL REVIEWS (2008)
Twelve immunotherapy drugs that could cure cancers
Martin A. ‘Mac’ Cheever
IMMUNOLOGICAL REVIEWS (2008)
STRATEGIES TO OVERCOME OBSTACLES TO SUCCESSFUL IMMUNOTHERAPY OF MELANOMA
F. Pandolfi et al.
INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY (2008)
Role of TGF-β in the Induction of Foxp3 Expression and T Regulatory Cell Function
Ethan M. Shevach et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2008)
Next generation of immunotherapy for melanoma
John M. Kirkwood et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Adjuvant therapy of melanoma with interferon: lessons of the past decade
Paolo A. Ascierto et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2008)
The tumor microenvironment and its role in promoting tumor growth
T. L. Whiteside
ONCOGENE (2008)
Identification of human aldehyde dehydrogenase 1 family member a1 as a novel CD8+ T-Cell-Defined tumor antigen in squamous cell carcinoma of the head and neck
Carmen Visus et al.
CANCER RESEARCH (2007)
Tumor microenvironment and immune escape
Soldano Ferrone et al.
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA (2007)
A unique subset of CD4+CD25high Foxp3+ T cells secreting interleukin-10 and transforming growth factor-β1 mediates suppression in the tumor microenvironment
Laura Strauss et al.
CLINICAL CANCER RESEARCH (2007)
Targeting human γδ T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer
Francesco Dieli et al.
CANCER RESEARCH (2007)
Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: A systematic review
Nicole M. Kuderer et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Immune signatures off murine and human cancers reveal unique mechanisms of tumor escape and new targets for cancer immunotherapy
Rebecca E. Sadun et al.
CLINICAL CANCER RESEARCH (2007)
Depletion of CD4+CD25+ human regulatory T cells in vivo:: Kinetics of Treg depletion and alterations in immune functions in vivo and in vitro
Karsten Mahnke et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4
Veronica Mata-Haro et al.
SCIENCE (2007)
Indoleamine 2,3-dioxygenase and tumor-induced tolerance
David H. Munn et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Development of TLR9 agonists for cancer therapy
Arthur M. Krieg
JOURNAL OF CLINICAL INVESTIGATION (2007)
Principles of adoptive T cell cancer therapy
Carl H. June
JOURNAL OF CLINICAL INVESTIGATION (2007)
Metronomic cyclophosphamide regimen selectively depletes CD4+ CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients
Francois Ghiringhelli et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
Selective inhibition of ADAM metalloproteases as a novel approach for modulating ErbB pathways in cancer
Jordan S. Fridman et al.
CLINICAL CANCER RESEARCH (2007)
Prospect of targeting the CD40 pathway for cancer therapy
Robert H. Vonderheide
CLINICAL CANCER RESEARCH (2007)
Indoleamine 2,3-dioxygenase in immune suppression and cancer
Alexander J. Muller et al.
CURRENT CANCER DRUG TARGETS (2007)
Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma
Augusto C. Ochoa et al.
CLINICAL CANCER RESEARCH (2007)
Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer
G. Valabrega et al.
ANNALS OF ONCOLOGY (2007)
Anti-tac (daclizumab, zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: A 25-year personal odyssey
Thomas A. Waldmann
JOURNAL OF CLINICAL IMMUNOLOGY (2007)
Cooperation of Toll-like receptor signals in innate immune defence
Giorgio Trinchieri et al.
NATURE REVIEWS IMMUNOLOGY (2007)
Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function
Paolo Serafini et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Interferons, immunity and cancer immunoediting
Gavin P. Dunn et al.
NATURE REVIEWS IMMUNOLOGY (2006)
Cancer regression in patients after transfer of genetically engineered lymphocytes
Richard A. Morgan et al.
SCIENCE (2006)
Blood dendritic cells generated with Flt3 ligand and CD40 ligand prime CD8+ T cells efficiently in cancer patients
Ian D. Davis et al.
JOURNAL OF IMMUNOTHERAPY (2006)
CTLA-4 overexpression inhibits T cell responses through a CD28-B7-dependent mechanism
John J. Engelhardt et al.
JOURNAL OF IMMUNOLOGY (2006)
Immune escape associated with functional defects in antigen-processing machinery in head and neck cancer
Robert L. Ferris et al.
CLINICAL CANCER RESEARCH (2006)
IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells
SA Rosenberg et al.
JOURNAL OF IMMUNOTHERAPY (2006)
Interleukin-15 rescues tolerant CD8+ T cells for use in adoptive immunotherapy of established tumors
RM Teague et al.
NATURE MEDICINE (2006)
Chronic inflammation, immunosuppression and cancer: New insights and outlook
M Baniyash
SEMINARS IN CANCER BIOLOGY (2006)
Immunotoxins for targeted cancer therapy
Robert J. Kreitman
AAPS JOURNAL (2006)
Paradoxical roles of the immune system during cancer development
KE de Visser et al.
NATURE REVIEWS CANCER (2006)
Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells
J Dannull et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells
L Gattinoni et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells
CA Klebanoff et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+CD25+ T regulatory cell activities in lung cancer
S Sharma et al.
CANCER RESEARCH (2005)
Monoclonal antibody therapy of cancer
GP Adams et al.
NATURE BIOTECHNOLOGY (2005)
Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: Tumor escape by antigen loss and loss of MHC expression
HT Khong et al.
JOURNAL OF IMMUNOTHERAPY (2004)
IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T Cells
CA Klebanoff et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
NF-κB functions as a tumour promoter in inflammation-associated cancer
E Pikarsky et al.
NATURE (2004)
Cancer immunotherapy: moving beyond current vaccines
SA Rosenberg et al.
NATURE MEDICINE (2004)
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
TJ Curiel et al.
NATURE MEDICINE (2004)
Antigen-processing machinery in human dendritic cells: Up-regulation by maturation and down-regulation by tumor cells
TL Whiteside et al.
JOURNAL OF IMMUNOLOGY (2004)
Interleukin-10 in viral diseases and cancer: exiting the labyrinth?
AP Vicari et al.
IMMUNOLOGICAL REVIEWS (2004)
Cancer immunotherapy: A treatment for the masses
JN Blattman et al.
SCIENCE (2004)
Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents
JR Baldridge et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2004)
Resiquimod: a new immune response modifier with potential as a vaccine adjuvant for Th1 immune responses
JJ Wu et al.
ANTIVIRAL RESEARCH (2004)
HLA class I antigen loss, tumor immune escape and immune selection
M Campoli et al.
VACCINE (2002)
Inhibition of CD40 expression and CD40-mediated dendritic cell function by tumor-derived IL-10
MR Shurin et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
CTLA-4: new insights into its biological function and use in tumor immunotherapy
JG Egen et al.
NATURE IMMUNOLOGY (2002)
Inducing tumor immunity through the selective engagement of activating Fcγ receptors on dendritic cells
AM Kalergis et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2002)
Interleukin-12 in anti-tumor immunity and immunotherapy
MP Colombo et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2002)
Structural diversity of heparan sulfate binding domains in chemokines
H Lortat-Jacob et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Prostaglandins as modulators of immunity
SG Harris et al.
TRENDS IN IMMUNOLOGY (2002)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
B7.1 on human carcinomas: Costimulation of T cells and enhanced tumor-induced T-cell death
S Lang et al.
CELLULAR IMMUNOLOGY (2000)
Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis
M Stolina et al.
JOURNAL OF IMMUNOLOGY (2000)
分享论文
